parkinsons disease - search results

Yesterday on World Parkinson's Day in the Journal of Parkinson's Disease, researchers revealed the potential environmental origins of Parkinson's disease.

Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.

In a groundbreaking collaboration, the Accelerated Capability Environment (ACE) has teamed up with the NHS's AI Skunkworks to harness AI to diagnose Parkinsons with unprecedented speed.

Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.

Parkinson’s Disease affects all activities of patient daily living but PKG can help.

Global Kinetics aim to improve the lives of those with Parkinson’s disease with advanced medical technologies.

A clinical trial at Oxford University has found that a drug used for rheumatoid arthritis can reverse Dupuytren’s disease, if taken early on.

Jacqueline Hoogendam, JPND’s newly elected Vice-Chair and Executive Board member talks about JPND’s past and present strategies in its outreach campaign within and beyond Europe.

The death rate from Parkinson’s disease has risen by 63% in the United States, according to a new study.

Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.

Professor Dame Pamela Shaw explains how the National Institute for Health Research (NIHR) supports experimental medicine and translational research in neurodegenerative diseases.

A new study published in the Movement Disorders journal, has paved the way for more research into identifying markers of progression for patients in the early stages of Parkinson’s disease

National Institutes of Health scientists develop new brain disease test for the early diagnosis of Parkinson’s disease and dementia with Lewy bodies The group, led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson’s disease, 17 from...

Ramón Cacabelos, President of EuroEspes Biomedical Research Centre looks at conventional pharmacological treatments for Parkinson’s disease

Dr Mehis Pilv, CEO and business development lead at Genecode, discusses the strides being made in Parkinson's disease research Parkinson's disease is a slow but progressive neurodegenerative disorder. About 1% of people aged above 50 are affected worldwide. In Europe alone 1.2 million people suffer from Parkinson's disease, 127,000 of whom...

Frédéric Destrebecq, Executive Director, and Vinciane Quoidbach, Public Health and Policy Project Manager at the European Brain Council, explain the socio-economic impact of interventions and the importance of early diagnosis with regard to brain disorders… Depression, stroke, dementia, alcohol dependence, schizophrenia or anxiety will affect at least one in three...

We spoke with Parkinson’s UK, an organisation dedicated to funding important research and supporting those affected by Parkinson’s, about the prevalence, impact, and management of the condition.

A group of researchers around the globe have created a portable, non-invasive device capable of identifying biomarkers associated with Alzheimer's and Parkinson's disease.

In an interview with Clair Mace, examined what the Personal KinetiGraph can really do for patients dealing with Parkinson’s disease.